Economic Burden of Heart Failure Hospitalizations in Canada: A Population-based Study

Emily E Ellis1,2, Hena Quereshi1,2, Douglas C Dover1,2

  • 1Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada.

CJC Open
|April 4, 2025
PubMed

Insights

Heart failure hospitalizations in Canada are rising, costing billions. Future projections indicate a significant increase in heart failure (HF) episodes and associated healthcare expenses, necessitating proactive health system planning.

Area of Science:

  • Cardiology
  • Health Economics
  • Public Health

Background:

  • Heart failure (HF) is a major cause of mortality, morbidity, and significant healthcare resource utilization.
  • Understanding the economic impact of HF hospitalizations is crucial for Canadian healthcare planning.

Purpose of the Study:

  • To examine hospitalization costs for patients with heart failure (HF) in Canada from 2010/2011 to 2018/2019.
  • To estimate future HF hospitalization costs up to 2039/2040.

Main Methods:

  • Analysis of hospitalization records with a primary diagnosis of HF between 2010/2011 and 2018/2019.
  • Calculation of total hospitalization costs and per-patient costs, adjusted to 2022 CAD$.
  • Projection of future HF hospitalization episodes and costs using generalized linear models and Statistics Canada population data.

Main Results:

  • HF hospitalization episodes increased from 43,114 to 54,743 between 2010/2011 and 2018/2019.
  • Total hospitalization costs for HF rose from $684.3 million to $776.0 million in the same period, totaling $6.65 billion cumulatively.
  • Projected 1.69 million HF hospitalization episodes between 2019/2020 and 2039/2040, with an estimated cost of $19.5 billion.

Conclusions:

  • Heart failure imposes a substantial and growing economic burden on the Canadian healthcare system.
  • Effective health system planning and policy interventions are required to mitigate future HF-related costs.
  • Strategies should focus on reducing hospitalization barriers, promoting effective HF therapies, and enhancing community-based care access.
Abstract

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.4K
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.2K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
284
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
331
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
298
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
445